Oshima Yoko, Shimada Hideaki, Yajima Satoshi, Nanami Tatsuki, Matsushita Kazuyuki, Nomura Fumio, Kainuma Osamu, Takiguchi Nobuhiro, Soda Hiroaki, Ueda Takeshi, Iizasa Toshihiko, Yamamoto Naoto, Yamamoto Hiroshi, Nagata Matsuo, Yokoi Sana, Tagawa Masatoshi, Ohtsuka Seiko, Kuwajima Akiko, Murakami Akihiro, Kaneko Hironori
Department of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
J Gastroenterol. 2016 Jan;51(1):30-4. doi: 10.1007/s00535-015-1078-8. Epub 2015 Apr 24.
Although serum NY-ESO-1 antibodies (s-NY-ESO-1-Abs) have been reported in patients with esophageal carcinoma, this assay system has not been used to study a large series of patients with various other cancers.
Serum samples of 1969 cancer patients [esophageal cancer (n = 172), lung cancer (n = 269), hepatocellular carcinoma (n = 91), prostate cancer (n = 358), gastric cancer (n = 313), colorectal cancer (n = 262), breast cancer (n = 365)] and 74 healthy individuals were analyzed using an originally developed enzyme-linked immunosorbent assay system for s-NY-ESO-1-Abs. The optical density cut-off value, determined as the mean plus three standard deviations for serum samples from the healthy controls, was fixed at 0.165. Conventional tumor markers were also evaluated in patients with esophageal carcinoma.
The positive rate of s-NY-ESO-1-Abs in patients with esophageal cancer (31 %) was significantly higher than that in the other groups: patients with lung cancer (13 %), patients with hepatocellular carcinoma (11 %), patients with prostate cancer (10 %), patients with gastric cancer (10 %), patients with colorectal cancer (8 %), patients with breast cancer (7 %), and healthy controls (0 %). The positive rate of s-NY-ESO-1-Abs was comparable to that of serum p53 antibodies (33 %), squamous cell carcinoma antigen (36 %), carcinoembryonic antigen (26 %), and CYFRA 21-1 (18 %) and gradually increased with the tumor stage.
The positive rate of s-NY-ESO-1-Abs was significantly higher in patients with esophageal cancer than in patients with the other types of cancers. On the basis of its high specificity and sensitivity, even in patients with stage I tumors, s-NY-ESO-1-Abs may be one of the first choices for esophageal cancer.
尽管食管癌患者中已报告有血清NY-ESO-1抗体（s-NY-ESO-1-Abs），但该检测系统尚未用于研究大量患有其他各种癌症的患者。
使用最初开发的用于检测s-NY-ESO-1-Abs的酶联免疫吸附测定系统，对1969例癌症患者[食管癌（n = 172）、肺癌（n = 269）、肝细胞癌（n = 91）、前列腺癌（n = 358）、胃癌（n = 313）、结直肠癌（n = 262）、乳腺癌（n = 365）]和74名健康个体的血清样本进行分析。将光密度临界值设定为健康对照血清样本平均值加三个标准差，固定为0.165。还对食管癌患者的传统肿瘤标志物进行了评估。
食管癌患者中s-NY-ESO-1-Abs的阳性率（31%）显著高于其他组：肺癌患者（13%）、肝细胞癌患者（11%）、前列腺癌患者（10%）、胃癌患者（10%）、结直肠癌患者（8%）、乳腺癌患者（7%）以及健康对照者（0%）。s-NY-ESO-1-Abs的阳性率与血清p53抗体（33%）、鳞状细胞癌抗原（36%）、癌胚抗原（26%）和细胞角蛋白19片段（CYFRA 21-1，18%）相当，并随肿瘤分期逐渐升高。
食管癌患者中s-NY-ESO-1-Abs的阳性率显著高于其他类型癌症患者。基于其高特异性和敏感性，即使是I期肿瘤患者，s-NY-ESO-1-Abs也可能是食管癌的首选检测指标之一。
